Você pesquisou por y - Revista Brasileira de Ginecologia e Obstetrícia
You searched for:"Márcia Neves de Carvalho"
We found (3) results for your search.Summary
Rev Bras Ginecol Obstet. 2004;26(6):429-433
DOI 10.1590/S0100-72032004000600002
OBJECTIVE: to correlate serum leptin concentration with bone mineral density (BMD) in postmenopausal women. METHODS: twenty-two healthy postmenopausal women were included in the present study. BMD was measured by dual energy X-ray absorptiometry at the lumbar spine and femoral neck. Serum leptin concentrations were determined using an immunoradiometric assay. Statistical analysis was performed by ANOVA and Dunn and Pearson's correlation tests. RESULTS: mean BMD values were 0.898 ± 0.140 g/cm² at the lumbar spine and 0.760 ± 0.152 g/cm² at the femoral neck. Mean serum leptin concentration was 17.2 ± 9.4 ng/ml and no significant differences were observed among women with normal BMD, osteopenia and osteoporosis (18.6 ± 7.8, 18.9 ± 9.9 and 15.6 ± 10.6, respectively; p > 0.05). No significant correlations were observed between serum leptin levels and BMD measurements at the lumbar spine and femoral neck, when the whole sample was considered and when patients were divided into groups with osteoporosis and/or osteopenia and a control group. We observed a positive significant correlation between serum leptin levels and body mass index (BMI) (r = 0.66; p = 0.0044). CONCLUSIONS: there was no direct correlation between leptin and BMD in postmenopausal women, although we observed positive significant correlation between leptin and BMI. This fact indicates a possible indirect effect of leptin on bone metabolism.
Summary
Rev Bras Ginecol Obstet. 2004;26(6):429-433
DOI 10.1590/S0100-72032004000600002
OBJECTIVE: to correlate serum leptin concentration with bone mineral density (BMD) in postmenopausal women. METHODS: twenty-two healthy postmenopausal women were included in the present study. BMD was measured by dual energy X-ray absorptiometry at the lumbar spine and femoral neck. Serum leptin concentrations were determined using an immunoradiometric assay. Statistical analysis was performed by ANOVA and Dunn and Pearson's correlation tests. RESULTS: mean BMD values were 0.898 ± 0.140 g/cm² at the lumbar spine and 0.760 ± 0.152 g/cm² at the femoral neck. Mean serum leptin concentration was 17.2 ± 9.4 ng/ml and no significant differences were observed among women with normal BMD, osteopenia and osteoporosis (18.6 ± 7.8, 18.9 ± 9.9 and 15.6 ± 10.6, respectively; p > 0.05). No significant correlations were observed between serum leptin levels and BMD measurements at the lumbar spine and femoral neck, when the whole sample was considered and when patients were divided into groups with osteoporosis and/or osteopenia and a control group. We observed a positive significant correlation between serum leptin levels and body mass index (BMI) (r = 0.66; p = 0.0044). CONCLUSIONS: there was no direct correlation between leptin and BMD in postmenopausal women, although we observed positive significant correlation between leptin and BMI. This fact indicates a possible indirect effect of leptin on bone metabolism.
Summary
Rev Bras Ginecol Obstet. 2004;26(7):573-578
DOI 10.1590/S0100-72032004000700010
PURPOSE: to evaluate the effects of raloxifene on plasma homocysteine concentration and lipid profile in postmenopausal women. METHODS: twenty-four healthy postmenopausal women, aged 50 to 70 years, with osteopenia and/or osteoporosis, were submitted to raloxifene therapy, 60 mg/day, for six months. Plasma homocysteine concentration was determined before and after three and six months of therapy, as well as total cholesterol, HDL-cholesterol LDL-cholesterol and triglyceride levels. Plasma homocysteine was measured by a polarized immunofluorescence assay and serum lipids by the enzymatic and colorimetric method. Data were analyzed statistically by ANOVA, Newman-Keuls test and Pearson's correlation test. RESULTS: a significant decrease in total cholesterol of 15.3% (227.6±56.3 vs 200.6±29.8 vs 192.8±32.1 mg/dl; p<0.001) and LDL-cholesterol of 21.4% (151.4±46.3 vs 122.7±29.4 vs 119.0±28.6 mg/dl; p<0.001), and a significant increase in HDL-cholesterol of 9.5% (44.7±10.8 vs 52.2±12.6 vs 49.0±10.8 mg/dl; p<0.05) were observed. There was no reduction in triglyceride levels (134.9±50.3 vs 127.5±50.0 vs 121.0±36.0 mg/dl; p>0.05). Although not significant, a decrease in homocysteine by 4.5% (11.7±3.0 vs 11.0±2.9 vs 11.2±2.1 muM/l; p>0.05) was observed between the pre-and posttreatment periods, with a significant negative correlation between basal levels and posttreatment percentual reduction (r=-0.71; p<0.0001). CONCLUSIONS: raloxifene treatment, 60 mg/day, for six months caused a significant decrease in total and LDL-cholesterol and an increase in HDL-cholesterol in postmenopausal women. Plasma homocysteine concentration tended to decrease, this effect being more favorable in patients with elevated baseline levels.
Summary
Rev Bras Ginecol Obstet. 2004;26(7):573-578
DOI 10.1590/S0100-72032004000700010
PURPOSE: to evaluate the effects of raloxifene on plasma homocysteine concentration and lipid profile in postmenopausal women. METHODS: twenty-four healthy postmenopausal women, aged 50 to 70 years, with osteopenia and/or osteoporosis, were submitted to raloxifene therapy, 60 mg/day, for six months. Plasma homocysteine concentration was determined before and after three and six months of therapy, as well as total cholesterol, HDL-cholesterol LDL-cholesterol and triglyceride levels. Plasma homocysteine was measured by a polarized immunofluorescence assay and serum lipids by the enzymatic and colorimetric method. Data were analyzed statistically by ANOVA, Newman-Keuls test and Pearson's correlation test. RESULTS: a significant decrease in total cholesterol of 15.3% (227.6±56.3 vs 200.6±29.8 vs 192.8±32.1 mg/dl; p<0.001) and LDL-cholesterol of 21.4% (151.4±46.3 vs 122.7±29.4 vs 119.0±28.6 mg/dl; p<0.001), and a significant increase in HDL-cholesterol of 9.5% (44.7±10.8 vs 52.2±12.6 vs 49.0±10.8 mg/dl; p<0.05) were observed. There was no reduction in triglyceride levels (134.9±50.3 vs 127.5±50.0 vs 121.0±36.0 mg/dl; p>0.05). Although not significant, a decrease in homocysteine by 4.5% (11.7±3.0 vs 11.0±2.9 vs 11.2±2.1 muM/l; p>0.05) was observed between the pre-and posttreatment periods, with a significant negative correlation between basal levels and posttreatment percentual reduction (r=-0.71; p<0.0001). CONCLUSIONS: raloxifene treatment, 60 mg/day, for six months caused a significant decrease in total and LDL-cholesterol and an increase in HDL-cholesterol in postmenopausal women. Plasma homocysteine concentration tended to decrease, this effect being more favorable in patients with elevated baseline levels.
Summary
Rev Bras Ginecol Obstet. 2007;29(2):96-102
DOI 10.1590/S0100-72032007000200007
PURPOSE: to evaluate the classification and the etiology of girls attended in a Pediatric and Adolescent Gynecology Clinic. METHODS: The hospital charts of 58 female patients attended from 2000 to 2005 with diagnosis of probable precocious puberty were reviewed and relevant data analyzed. Inclusion criteria were breast and/or pubic hair growth before eight years old. The girls were classified according to the clinic aspects and the supplementary exams they had been submitted to, into one of the categories: central precocious puberty (CPP), precocious pseudopuberty, premature thelarche and premature pubarche. RESULTS: from the 58 reviewed cases, 28 girls were diagnosed as CPP, one as precocious pseudopuberty, ten as premature thelarche and 19 as premature pubarche. All the cases of CPP had an idiopathic etiology, except for one girl whose activation of the ypothalamic-pituitary-gonadal axis was secondary to congenital adrenal hyperplasia. There was one case of precocious pseudopuberty due to McCune-Albright syndrome. All the cases of premature thelarche had an idiopathic etiology, except for one girl who had primary hypothyroidism. All the cases of premature pubarche had an idiopathic etiology. CONCLUSIONS: among the cases diagnosed as precocious puberty, CPP was the leading diagnosis and most cases had an idiopathic etiology. Organic causes leading to precocious puberty were infrequent.
Summary
Rev Bras Ginecol Obstet. 2007;29(2):96-102
DOI 10.1590/S0100-72032007000200007
PURPOSE: to evaluate the classification and the etiology of girls attended in a Pediatric and Adolescent Gynecology Clinic. METHODS: The hospital charts of 58 female patients attended from 2000 to 2005 with diagnosis of probable precocious puberty were reviewed and relevant data analyzed. Inclusion criteria were breast and/or pubic hair growth before eight years old. The girls were classified according to the clinic aspects and the supplementary exams they had been submitted to, into one of the categories: central precocious puberty (CPP), precocious pseudopuberty, premature thelarche and premature pubarche. RESULTS: from the 58 reviewed cases, 28 girls were diagnosed as CPP, one as precocious pseudopuberty, ten as premature thelarche and 19 as premature pubarche. All the cases of CPP had an idiopathic etiology, except for one girl whose activation of the ypothalamic-pituitary-gonadal axis was secondary to congenital adrenal hyperplasia. There was one case of precocious pseudopuberty due to McCune-Albright syndrome. All the cases of premature thelarche had an idiopathic etiology, except for one girl who had primary hypothyroidism. All the cases of premature pubarche had an idiopathic etiology. CONCLUSIONS: among the cases diagnosed as precocious puberty, CPP was the leading diagnosis and most cases had an idiopathic etiology. Organic causes leading to precocious puberty were infrequent.